Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | HTR2B | P41595 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19214342 | 0.70 | HTR2C (0.39) | TDP1TLR9TLR8TLR7HTR2A | |
| SCHEMBL19217956 | 0.69 | NR1H2 (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL17504927 | 0.67 | NR1H2 (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL19214346 | 0.66 | NR1H2 (0.37) | TDP1TLR9TLR8TLR7HTR2A | |
| SCHEMBL10219346 | 0.65 | PPARD (0.53) | — | |
| SCHEMBL38664196 | 0.62 | ADRB2 (0.46) | TDP1TLR9TLR8TLR7HTR2A | |
| SCHEMBL27619754 | 0.62 | TLR9 (0.37) | TDP1TLR9TLR8TLR7HTR2A | |
| SCHEMBL1911602 | 0.62 | SCD (0.36) | — | |
| SCHEMBL25933223 | 0.61 | AR (0.59) | TDP1 | |
| SCHEMBL28239838 | 0.61 | SLC6A2 (0.53) | TDP1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226067-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226067-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | NR1H2, NR1H3, NR1I2 | TDP1 2433/4885TLR9 1455/4885TLR8 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.